Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    TopAbstracts in Cholesterol/Lipid Disorders 11/26/2009 - (DGNews)
    Statins Can Reduce Risk of Major Cardiovascular Events in Healthy Women: Presented at AHA - (DGDispatch)
    Trends in High Levels of Low-Density Lipoprotein Cholesterol in the United States, 1999-2006 - (JAMA)
    Atorvastatin Improves Renal Function in Patients With Heart Disease, Metabolic Syndrome: Presented at AHA - (DGDispatch)
    Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness - (N Engl J Med)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
      Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Diabetes and the Heart: Cardiac Care for the Patient with Diabetes: Clinical Horizons
      High-Density Lipoprotein and the Epidemiology of Coronary Heart Disease
      Diabetes Management - Pearls of Lipid Control
      Initiating and Monitoring Statin Therapy

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        Lipemic Serum In Hyperlipidemic Pancreatitis
        There May be a Link Between Intrahepatic Cholestasis of Pregnancy and Familial Combined Hyperlipidaemia: A Case Report
        Marked Aortic Valve Stenosis Progression After Receiving Long-Term Aggressive Cholesterol-Lowering Therapy Using Low-Density Lipoprotein Apheresis in a Patient With Familial Hypercholesterolemia
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Combination of Simvastatin/Ezetimibe Reduces C-Reactive Protein Better Than Simvastatin Alone: Presented at ACC

        By Ed Susman

        ATLANTA, G.A. -- March 15, 2006 -- A combination of the anticholesterol drugs simvastatin (Zocor) and ezetimibe (Zetia) work together to reduce C-reactive protein, a marker of inflammation in the vascular system, better than either drug alone.

        "The combined therapy was significantly better in lowering LDL-cholesterol compared to monotherapy, and it was significantly better in lowering C-reactive protein markers compared to monotherapy," said Christie M. Ballantyne, MD, associate chief and professor of medicine, section of atherosclerosis and lipoprotein research, Baylor College of Medicine, Houston, Texas.

        In his oral presentation on March 13th at the 55th Annual Scientific Session of the American College of Cardiology (ACC), Dr. Ballantyne said, "Ezetimibe/simvastatin provided enhanced lipid regulation and anti-inflammatory effects compared to simvastatin alone."

        He and colleagues prepared a post hoc analysis of 3 similar, randomized, placebo-controlled, double-blind studies that included 3083 people with hypercholesterolemia. In the studies, patients were taken off medicines for 4 to 6 weeks and were then equally randomized to placebo, ezetimibe 10 mg, ezetimibe/simvastatin 10 mg/10 mg, ezetimibe/simvastatin 10 mg/20 mg, ezetimibe/simvastatin 10 mg/40 mg, ezetimibe/simvastatin 10 mg/80 mg, simvastatin 10 mg, simvastatin 20 mg, simvastatin 40 mg, or simvastatin 80 mg. Subjects in the studies were on treatment for 12 weeks.

        Pooled data shows that simvastatin was successful in lowering C-reactive protein values 14.3% from baseline. While ezetimibe, by itself, did not significantly reduce levels of C-reactive protein, the combination of simvastatin and ezetimibe -- the same combination that forms the cholesterol-lowering drug Vytorin -- reduced C-reactive protein levels by 31%. The difference between the 2 drugs and simvastatin alone was statistically significant at the P <.001 level, Dr. Ballantyne said.

        When it came to decreasing cholesterol levels, the same pattern was seen, he said. By itself, simvastatin lowered cholesterol 38%, while together the 2 drugs reduced cholesterol 52.5% in the pooled data, Dr. Ballantyne said.


        [Presentation title: Effects of Ezetimibe/Simvastatin Compared to Simvastatin Monotherapy in Reducing C-Reactive Protein and Low-Density Lipoprotein Cholesterol. Abstract 808-5]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send